Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

Toward a Biology-Driven Treatment Strategy for Peripheral T-cell Lymphoma.

Hildyard C. et al, (2017), Clin Med Insights Blood Disord, 10

Toward a biology-driven treatment strategy for peripheral T-cell lymphoma

Hildyard CAT. et al, (2017), Clinical Medicine Insights: Blood Disorders, 10

Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma

Goding C. et al, (2016), Genes and Development

A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma

Collins GP. et al, (2016), BLOOD, 128

Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Timmerman JM. et al, (2016), BLOOD, 128

Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade)

Roemer MGM. et al, (2016), BLOOD, 128

Correlation Between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Essential Thrombocythemia

Harrison CN. et al, (2016), BLOOD, 128

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma

Armand P. et al, (2016), BLOOD, 128

Results of a Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CXD101: Preliminary Safety and Activity in Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma Patients

Eyre TA. et al, (2016), BLOOD, 128

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

Noy A. et al, (2016), BLOOD, 128

First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies

Postel-Vinay S. et al, (2016), EUROPEAN JOURNAL OF CANCER, 69, S7 - S8

Initial seeding of the embryonic thymus by immune-restricted lympho-myeloid progenitors.

Luis TC. et al, (2016), Nat Immunol, 17, 1424 - 1435

Preliminary biomarker and pharmacokinetic analysis from the completed dose escalation part of the first-in-human Phase I study evaluating MP0250, a multi-DARPin (R) blocking HGF and VEGF-A, in patients with advanced solid tumors

Dawson K. et al, (2016), EUROPEAN JOURNAL OF CANCER, 69, S133 - S133

TARDOX: Safety and Feasibility of Targeted Delivery of Lyso-Thermosensitive Liposomal Doxorubicin (ThermoDox®) By Focused-Ultrasound Hyperthermia for Liver Tumours

Odondi LET. et al, (2016)

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

Blagden SP., (2016), Annals of Oncology

Loss of LARP4B, an early event in the tumorigenesis of brain cancer?

Blagden S. et al, (2016), TRANSLATIONAL CANCER RESEARCH, 5, S1196 - S1199

Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP.

Lu M. et al, (2016), Cancer cell, 30, 822 - 823

RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.

Gupta A. et al, (2016), British Journal of Cancer

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer

Parkes EE. et al, (2016), Journal of the National Cancer Institute, 109, djw199 - djw199

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence

Harrison CN. et al, (2016), Leukemia and Lymphoma, 57, 2259 - 2267